Mounjaro (tirzepatide) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus in adults
Side Effect Profiles Whether semaglutide comes in a pill or injection, the most common side effects are the same: Stomach pain Yellow skin or eyes Fever Sweating Dizziness Anxiety Nausea Bloating Vomiting Constipation Diarrhea Faster heartbeat Shakiness or weakness Headaches Blurred vision Fatigue Interestingly, oral and injectable options have about the same risk of adverse side effects
Posted images are actual R+H patients who have signed photo release consents
Qualifying Comorbidities FDA labeling and clinical guidelines commonly recognize: Hypertension (blood pressure 130/80 or taking antihypertensive medication) Type 2 diabetes (HbA1c 6.5% or on glucose-lowering medication) Prediabetes (HbA1c 5.7-6.4% or impaired fasting glucose) Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides) Obstructive sleep apnea (diagnosed via sleep study) Cardiovascular disease (prior MI, stroke, coronary artery disease) Non-alcoholic fatty liver disease / MASLD Polycystic ovary syndrome (PCOS) with metabolic features Osteoarthritis weight-bearing joints Insurance formularies may be stricter some require objective documentation (lab values, sleep study reports) rather than self-report
Semaglutide is a GLP-1 receptor agonist that helps millions manage weight by slowing stomach emptying and affecting appetite centers in the brain
Kim said that treating prediabetes not only prevents diabetes, but prediabetes is a risk factor for other chronic conditions